- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Lexeo Therapeutics GAAP EPS of -$0.30 misses by $0.01 | 1 | Seeking Alpha | ||
| 12.08. | Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights | 1.483 | GlobeNewswire (Europe) | Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first... ► Artikel lesen | |
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy | 185 | GlobeNewswire (Europe) | RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations... ► Artikel lesen | |
| 15.07. | What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple | 4 | Insider Monkey | ||
| 29.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | Lexeo publishes phase I/II data for gene therapy LX2006 | 1 | Investing.com | ||
| 17.06. | Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia | 1 | GlobeNewswire (USA) | ||
| 15.06. | Why Is Lexeo Therapeutics Stock Gaining Monday? | 1 | Benzinga.com | ||
| 15.06. | Lexeo finalizes pivotal trial design for gene therapy LX2006 | 3 | Investing.com | ||
| 15.06. | Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia | 283 | GlobeNewswire (Europe) | SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing... ► Artikel lesen | |
| 15.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | Raymond James reiterates Strong Buy on Lexeo stock, $25 target | 7 | Investing.com | ||
| 11.05. | Lexeo Therapeutics GAAP EPS of -$0.25 | 1 | Seeking Alpha | ||
| 11.05. | Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights | 393 | GlobeNewswire (Europe) | SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine... ► Artikel lesen | |
| 11.05. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.04. | Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 5 | GlobeNewswire (USA) |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,945 | +1,24 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,970 | -2,61 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 709,20 | -1,55 % | Dividendenbekanntmachungen (18.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATKORE INC US0476491081 0,33 USD 0,285 EUR AVISTA CORPORATION US05379B1070 0,4925 USD 0,4253 EUR BWX TECHNOLOGIES INC US05605H1005 0... ► Artikel lesen | |
| OCUGEN | 1,196 | -5,38 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,106 | -0,36 % | INOVIO shares jump 18% after Q2 beat | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | SANGAMO THERAPEUTICS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| VIKING THERAPEUTICS | 29,450 | -4,38 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INFLARX | 1,780 | -2,20 % | InflaRx NV: Durchbruch in der Immuntherapie weckt weltweites Interesse | ||
| INTELLIA THERAPEUTICS | 10,700 | -5,98 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,125 | +0,45 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,656 | +0,42 % | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| ABIVAX | 101,50 | -2,22 % | Abivax-Aktie: Übernahme voraus? Das spricht jetzt für einen Einstieg | Die Abivax-Aktie steht nach dem jüngsten Rücksetzer wieder an einer entscheidenden Marke. Während der Kurs zuletzt bis knapp unter 104 Euro beziehungsweise 120 US-Dollar gefallen ist, bleibt im Hintergrund... ► Artikel lesen | |
| IBIO | 1,190 | -7,03 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 6,790 | -2,44 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,270 | -3,79 % | H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,045 Euro und damit -6,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.